Wegovy Wegovy is a weekly weight loss injection that contains the active ingredient semaglutide
2001;86(11):5509-5515 Melmed S
Exercise maintains weight loss after GLP-1 deprescription In 2025, some insurance companies are updating the rules to narrow the qualifications for being prescribed the drug
Freshly Uncovered News and Studies In July 2023, a wave of stories emerged shedding light on the challenges faced by individuals using Ozempic and Wegovy who were later diagnosed with gastroparesis
Weight loss results can vary, with some patients starting to see changes in a few weeks to a month when taking the appropriate dose
However, many patients present with extraintestinal manifestations such as iron-deficiency anemia, osteoporosis, dermatitis herpetiformis, elevated liver enzymes, neurological symptoms, or infertility